Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germany's Growth Story

This article was originally published in Start Up

Executive Summary

Germany's biotech investment has propelled a handful of companies onto the public markets a lot sooner than their US or UK counterparts. These German companies have followed aggressive acquisition strategies, most often buying into the US, sometimes using newly-minted Neuer Markt paper. Some are seeking through these acquisitions to both broaden their technology platform and acquire a product portfolio, hoping thereby to avoid the pitfalls of a narrow focus. It's too early to tell whether such a dual model will work. But the fact that Germany's young companies are finding their own approach to competing globally shows that the country's biotech initiative has already had some success.

You may also be interested in...



Public Venture Capital for Israel's Biotech Industry

Israeli biotech is hot -- lots of ideas and lots of entrepreneurs. But the industry is chronically short of management and venture money. For the latter, companies have turned to Israel's recently deregulated stock market.

Public Venture Capital for Israel's Biotech Industry

Israeli biotech is hot -- lots of ideas and lots of entrepreneurs. But the industry is chronically short of management and venture money. For the latter, companies have turned to Israel's recently deregulated stock market.

The IP Land Grab: New UK Tech Transfer Models

As VCs continue to woo later-stage assets, a new breed of companies has stepped in upstream to help UK universities commercialize their IP. The models vary, and it's unclear how successful they'll be either for investors, or for universities. But the attention and money they're attracting to the area are welcome.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC090358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel